|
Characteristics
|
Overall
|
BRAF inhibitor treated
|
|---|
|
N
|
(%)
|
N
|
(%)
|
|---|
|
Patients
|
64
|
(100)
|
33
|
(100)
|
|
Sex
|
|
Male
|
35
|
(54.7)
|
17
|
(51.5)
|
|
Female
|
29
|
(45.3)
|
16
|
(48.5)
|
|
Age
|
|
Median (range)
|
61 (22–82)
|
─
|
53 (22–82)
|
─
|
|
Site of primary melanoma
|
|
Skin
|
54
|
(84.4)
|
29
|
(87.9)
|
|
Unknown
|
8
|
(12.5)
|
4
|
(12.1)
|
|
Uveal
|
2
|
(3.1)
|
0
|
(0)
|
|
Stage at diagnosis
|
|
I
|
1
|
(1.6)
|
1
|
(3.1)
|
|
II
|
19
|
(30.1)
|
8
|
(24.2)
|
|
III
|
26
|
(41.3)
|
14
|
(42.4)
|
|
IV
|
17
|
(27)
|
10
|
(30.3)
|
|
Metastatic stage
|
|
M1a
|
13
|
(20.3)
|
7
|
(21.2)
|
|
M1b
|
9
|
(14.1)
|
6
|
(18.2)
|
|
M1c
|
42
|
(65.6)
|
20
|
(60.6)
|
|
Brain metastasis
|
|
No
|
41
|
(64.1)
|
23
|
(69.7)
|
|
Yes
|
23
|
(35.9)
|
10
|
(30.3)
|
|
N° metastasis
|
|
≤ 2
|
28
|
(43.7)
|
13
|
(39.4)
|
|
> 2
|
36
|
(56.3)
|
20
|
(60.6)
|
|
DFS
|
|
Median (range)
|
12 (0–144)
|
─
|
12 (0–136)
|
─
|
|
OS
|
|
Median (range)
|
32 (2–182)
|
─
|
31.5 (5–145)
|
─
|
|
OSMD
|
|
Median (range)
|
12.5 (2–86)
|
─
|
14 (4–54)
|
─
|
- DFS disease free survival, OS overall survival, OSMD overall survival from metastatic disease
- For one patient the stage at diagnosis was unknown
